Cocrystal containing camostat and niclosamide, pharmaceutical composition containing the same, and method for producing the same

Abstract

The present invention relates to a novel cocrystal, a pharmaceutical composition containing the same, and a method for producing the same. The cocrystal of the present invention can be used to effectively prevent and / or treat cancer, inflammatory diseases, or viral infections.

Description

[Technical Field]

[0001] The present invention relates to a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide; or a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer; a pharmaceutical composition comprising the same, and a method for preparing the same. [Background technology]

[0002] A cocrystal is a form in which two or more different molecules form a crystal structure in a single crystal lattice at a certain stoichiometric ratio. The different molecules in a cocrystal, two or more drugs, or a drug and a co-former, can form a crystal structure in a single crystal lattice and are bonded by hydrogen bonds, van der Waals bonds, or π-π stacking interactions, which distinguishes them from salts and mixtures. Although cocrystals are already known, the overall research into them is insufficient, accounting for less than 1% of the research into common organic compounds. Camostat is a drug represented by Chemical Formula 1 below, and its salt, camostat mesylate, is a drug represented by Chemical Formula 2 below. These are anticoagulants that are used as therapeutic agents for pancreatitis, and are also known to have potential antiviral and anticancer effects. Recently, it has been reported that camostat inhibits the activity of TMPRSS2 on the cell surface, making it a useful compound for the treatment and prevention of, for example, coronavirus disease 2019 (COVID-19), which requires TMPRSS2 S protein priming. <C1> JPEG0007733935000001.jpg60154<2> JPEG0007733935000002.jpg69163Niclosamide is a drug represented by the following formula 3. <3> Niclosamide has very low aqueous solubility and intestinal permeability, resulting in extremely low bioavailability. Therefore, excessive amounts of niclosamide are typically administered orally. However, the properties of niclosamide itself make it difficult to expect any beneficial effects from systemic exposure. In particular, its low solubility limits the therapeutic or ameliorative effects that can be achieved. [Prior art document] (Non-Patent Document 0001) Ko, M., Jeon, S., Ryu, WS, & Kim, S. (2020.08.07). Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. Journal of medical virology. Summary of the Invention [Problem to be solved by the invention]

[0003] The present invention provides a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide; a pharmaceutical composition comprising the same; and a method for producing the same. The present invention provides a pharmaceutical composition for the prevention or treatment of cancer, an inflammatory disease, or a viral infection, comprising a cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide. The present invention provides a method for preventing or treating cancer, an inflammatory disease, or a viral infection, comprising administering to an individual a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, and niclosamide. The present invention provides use of a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide for the prevention or treatment of cancer, an inflammatory disease, or a viral infection disease. The present invention provides use of a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide for the manufacture of a medicament for the prevention or treatment of cancer, an inflammatory disease, or a viral infection disease. The present invention provides a co-crystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former; a pharmaceutical composition comprising the same; and a method for preparing the same. The present invention provides a method for preventing or treating cancer, an inflammatory disease, or a viral infection, comprising administering to an individual a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former. The present invention provides use of a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer for the prevention or treatment of cancer, an inflammatory disease, or a viral infection disease. The present invention provides use of a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer for the manufacture of a medicament for the prevention or treatment of cancer, an inflammatory disease, or a viral infection disease. [Means for solving the problem]

[0004] The inventors attempted to maximize the efficacy of niclosamide, which acts primarily inside cells, and camostat, which inhibits viral entry into cells outside the cells, by simultaneously administering these drugs. As a result, the present inventors have produced cocrystals containing camostat or a pharmaceutically acceptable salt thereof and niclosamide; or cocrystals containing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer, thereby producing cocrystals with improved solubility and permeability of the individual drugs, and have confirmed the excellent efficacy of these cocrystals, thereby completing the present invention. The present invention will be described in more detail below. Each description and embodiment disclosed in the present invention may be applied to other descriptions and embodiments. That is, all combinations of various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention is not limited by the specific description set forth below. Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Terms as defined in commonly used dictionaries should be interpreted to have a meaning consistent with the meaning they have in the context of the relevant art, and should not be interpreted in an idealized or overly formal sense unless expressly defined in this application.

[0005] Cocrystals The present invention provides a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide. The cocrystal is a fused crystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide, and may refer to a cocrystal of camostat or a pharmaceutically acceptable salt thereof and niclosamide. The cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide has improved solubility, bioavailability, and biomembrane permeability, and can be useful for treating cancer, inflammatory diseases, and viral infections. Furthermore, the cocrystal has significantly increased solubility and bioavailability compared to existing single substances, niclosamide or camostat, and has improved solubility and biomembrane permeability, making it effective for the prevention and / or treatment of cancer, inflammatory bowel disease, or viral infections such as coronavirus. Furthermore, the cocrystal is economical because it is safe, easy to store, and easy to manufacture, allowing for simple mass production. In one embodiment of the present invention, the cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide may exhibit an endothermic peak at 144.38±3°C in differential scanning calorimetry (DSC) when the heating rate is 10°C / min. The co-crystal may have a powder X-ray diffraction (XRD) pattern including diffraction peaks at diffraction angle 2θ (±0.2°) values ​​of 5.37715°, 15.1122°, 18.2258°, 18.7579°, 20.3344°, 25.596°, and 26.069°. In addition, the cocrystal may further include a powder X-ray diffraction (XRD) pattern containing diffraction peaks at at least one diffraction angle 2θ (±0.2°) of 10.6979°, 13.1612°, 17.7134°, 26.4434°, and 27.882°. In one embodiment of the present invention, the cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide may exhibit an endothermic peak at 126.35±3°C in differential scanning calorimetry (DSC) when the heating rate is 10°C / min. The co-crystal may have a powder X-ray diffraction (XRD) pattern including diffraction peaks at diffraction angle 2θ (±0.2°) values ​​of 6.55954°, 10.7176°, 18.147°, 19.5855°, 21.3591°, and 26.8178°. The cocrystal may further have a powder X-ray diffraction (XRD) pattern that includes diffraction peaks at at least one diffraction angle 2θ (±0.2°) of 13.8509°, 15.2501°, 16.6296°, 20.9059°, 22.3642°, 24.3151°, 24.8866°, and 27.7637°. In one embodiment of the present invention, the cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide may exhibit an endothermic peak at 182.74±3°C in differential scanning calorimetry (DSC) when the heating rate is 10°C / min. The co-crystal may have a powder X-ray diffraction (XRD) pattern including diffraction peaks at diffraction angle 2θ (±0.2°) values ​​of 11.3876°, 16.0975°, 16.6493°, 18.679°, 23.0539°, 23.9013°, 24.4333°, and 29.7344°. The cocrystal may further have a powder X-ray diffraction (XRD) pattern that includes diffraction peaks at at least one diffraction angle 2θ (±0.2°) of 7.82075°, 18.679°, 19.0929°, 22.6992°, 25.4975°, 26.9755°, and 30.365°. In one embodiment of the present invention, the cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide may exhibit an endothermic peak at 151.69±3°C in differential scanning calorimetry (DSC) when the heating rate is 10°C / min. The co-crystal may have a powder X-ray diffraction (XRD) pattern including diffraction peaks at diffraction angle 2θ (±0.2°) values ​​of 6.81572°, 7.46604°, 9.87023°, 12.3532°, 13.24°, and 18.6396°. The cocrystal may further have a powder X-ray diffraction (XRD) pattern that includes diffraction peaks at at least one diffraction angle 2θ (±0.2°) of 12.8262°, 22.6795°, 23.259°, 24.7881°, 25.6946°, and 27.5667°. The present invention also provides a cocrystal containing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former. The cocrystal is a fused crystal containing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former, and may refer to a cocrystal composed of camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former. The cocrystal containing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer has improved solubility, bioavailability, and biomembrane permeability, and can be useful for treating cancer, inflammatory diseases, and viral infections. Furthermore, the cocrystal has significantly increased solubility and bioavailability compared to existing single substances, niclosamide or camostat, and due to its improved solubility and permeability, can be effectively used for the prevention and / or treatment of cancer, inflammatory bowel disease, or viral infections such as coronavirus. Furthermore, the cocrystal is economical because it is safe, easy to store, and easy to manufacture, allowing for simple mass production. In one embodiment of the present invention, the cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer may exhibit an endothermic peak at 126.03°C in differential scanning calorimetry (DSC) when the heating rate is 10°C / min. The co-crystal may have a powder X-ray diffraction (XRD) pattern including diffraction peaks at diffraction angle 2θ (±0.2°) values ​​of 7.0522°, 7.6239°, 9.06226°, 12.4912°, 18.009°, and 21.9897°. In addition, the cocrystal may further include a diffraction peak in the powder X-ray diffraction (XRD) pattern at at least one diffraction angle 2θ (±0.2°) between 24.2166° and 27.1134°. The cocrystal of the present invention may have a molar ratio of camostat or a pharmaceutically acceptable salt thereof to niclosamide of about 1:4 to 4:1, more specifically, about 1:1. When the cocrystal of the present invention includes a coformer, it can contain about 1 to 6 moles of the coformer per mole of camostat or a pharmaceutically acceptable salt thereof, or niclosamide, and more specifically, it can contain about 5 moles. The coformer is not particularly limited as long as it is pharmaceutically acceptable, and may be one or more selected from meglumine, histidine, arginine, nicotinamide, benzoate, formic acid, sorbic acid, citrolic acid (citric acid), malic acid, caffeine, theophylline, urea, etc. In one embodiment of the present invention, the coformer may be meglumine, nicotinamide, caffeine, arginine, or citrolic acid (citric acid). In the present invention, the term "cocrystal" refers to a form in which two or more different molecules form a crystal structure in a single crystal lattice at a certain stoichiometric ratio, and the intermolecular bonding form within a cocrystal is distinguished from that of a salt or a mixture. In the present invention, "the cocrystal of the present invention," "the cocrystal of the present invention," or a cocrystal that can be interpreted as referring to the cocrystal of the present invention refers to all of the cocrystals containing camostat or a pharmaceutically acceptable salt thereof and niclosamide; and all of the cocrystals of the present invention containing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former. In the present invention, the "pharmaceutically acceptable salt" is not particularly limited as long as it is a salt prepared by a conventional method known to those of ordinary skill in the art. For example, a pharmaceutically acceptable salt of camostat may be a sulfonate prepared from one or more acids selected from methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and naphthalenesulfonic acid. In one embodiment of the present invention, the pharmaceutically acceptable salt may be a methanesulfonate, i.e., a mesylate. In one embodiment of the present invention, the pharmaceutically acceptable salt of camostat in the cocrystal may be camostat mesylate. In the present invention, the term "co-former" refers to a pharmacologically inactive molecule that changes the crystalline form of a solid drug through the formation of a co-crystal, clathrate, or other crystalline solid form, and may refer to an inactive molecule among the molecules that constitute the crystal of a co-crystal. The cocrystal of the present invention may have a structure in which one molecule of niclosamide is bound to one molecule of camostat or a pharmaceutically acceptable salt of camostat, or a structure in which one molecule of niclosamide is bound to one molecule of camostat or a pharmaceutically acceptable salt of camostat and one or more molecules of a coformer. Other cocrystals with various binding ratios may also be included.

[0006] Method for producing cocrystals The present invention provides a method for producing a cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide, which comprises mixing and fusing camostat or a pharmaceutically acceptable salt thereof and niclosamide to form a cocrystal. In one embodiment of the present invention, the co-crystallization step can include mixing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a solvent. Specifically, the co-crystallization step can include mixing camostat or a pharmaceutically acceptable salt thereof, and niclosamide in a solvent to prepare a mixed solution; and obtaining a co-crystal from the mixed solution. For example, camostat or a pharmaceutically acceptable salt thereof and niclosamide can be crystallized in the mixed solution to obtain a co-crystal, and the co-crystal synthesized in the mixed solution can be separated into a dry powder form. The solvent may be at least one selected from water, a linear or branched alcohol having 1 to 5 carbon atoms, acetone, acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), ethyl acetate, toluene, hexane, tetrahydrofuran, etc. Examples of the alcohol may be at least one selected from methanol, ethanol, 2-propanol, n-propanol, etc., but are not limited thereto. In one embodiment of the present invention, camostat or a pharmaceutically acceptable salt thereof and niclosamide may be mixed and fused in a molar ratio of about 1:4 to 4:1, more specifically about 1:1, or may be mixed and fused in various other ratios. The step of removing the solvent to obtain the co-crystal may include filtering the mixed solution to remove the solvent, and then drying the mixed solution under reduced pressure. Through the drying process, a solid co-crystal powder can finally be obtained. In one embodiment of the present invention, camostat mesylate may be used as the salt of camostat. The present invention provides a method for preparing a cocrystal containing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer, the method comprising the step of mixing and fusing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer to allow crystallization. In one embodiment of the present invention, the co-crystallization step may include mixing camostat or a pharmaceutically acceptable salt thereof, niclosamide, a co-former, and a solvent. Specifically, the co-crystallization step may include mixing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former in a solvent to prepare a mixed solution; and obtaining a co-crystal from the mixed solution. For example, camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former may be crystallized in the mixed solution to obtain a co-crystal, and the co-crystal synthesized in the mixed solution may be separated into a dry powder form. In one embodiment of the present invention, camostat or a pharmaceutically acceptable salt thereof and niclosamide may be mixed and fused in a molar ratio of about 1:4 to 4:1, more specifically about 1:1, or may be mixed and fused in various other ratios. The coformer may be included in an amount of about 1 mole to 6 moles, more specifically about 5 moles, per mole of camostat or a pharmaceutically acceptable salt thereof, or niclosamide. Specifically, the molar ratio of camostat or a pharmaceutically acceptable salt thereof, niclosamide, and the coformer may be 1:1:1 to 1:1:6. The matters mentioned in the method for producing a cocrystal containing camostat or a pharmaceutically acceptable salt thereof, and niclosamide can be similarly applied to the solvent and the step of removing the solvent to obtain a cocrystal in the method for producing a cocrystal containing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer. In addition to the above-described preparation methods, the cocrystal of the present invention can be prepared using various combinations depending on the ratio of the drug components, the type of alkalizing agent, the type and ratio of the solvent, etc. The cocrystal of the present invention may be a crystal in which camostat or a pharmaceutically acceptable salt thereof and niclosamide are all present in a single crystal lattice, or a crystal in which camostat or a pharmaceutically acceptable salt thereof, niclosamide, and the coformer are all present in a single crystal lattice. The cocrystal of the present invention and its manufacturing method are as follows: 1. A cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide. 2. The cocrystal according to item 1 above, which is composed of camostat or a pharmaceutically acceptable salt thereof and niclosamide. 3. The cocrystal according to items 1 and 2 above, wherein the molar ratio of camostat or a pharmaceutically acceptable salt thereof to niclosamide is 1:4 to 4:1. 4. The cocrystal according to items 1 and 2 above, wherein the molar ratio of camostat or a pharmaceutically acceptable salt thereof to niclosamide is 1:1. 5. A cocrystal according to any one of items 1 to 4 above, wherein the powder X-ray diffraction (XRD) pattern includes diffraction peaks at diffraction angles 2θ (±0.2°) of 5.37715°, 15.1122°, 18.2258°, 18.7579°, 20.3344°, 25.596°, and 26.069°. 6. A cocrystal according to any one of items 1 to 4 above, which exhibits an endothermic peak in differential scanning calorimetry (DSC) at 144.38±3°C when the heating rate is 10°C / min. 7. A cocrystal according to any one of items 1 to 4 above, wherein the powder X-ray diffraction (XRD) pattern includes diffraction peaks at diffraction angles 2θ (±0.2°) of 6.55954°, 10.7176°, 18.147°, 19.5855°, 21.3591°, and 26.8178°. 8. A cocrystal according to any one of items 1 to 4 above, which exhibits an endothermic peak in differential scanning calorimetry (DSC) at 126.35±3°C when the heating rate is 10°C / min. 9. A cocrystal according to any one of items 1 to 4 above, wherein the powder X-ray diffraction (XRD) pattern includes diffraction peaks at diffraction angles 2θ (±0.2°) of 11.3876°, 16.0975°, 16.6493°, 18.679°, 23.0539°, 23.9013°, 24.4333°, and 29.7344°. 10. A cocrystal according to any one of items 1 to 4 above, which exhibits an endothermic peak in differential scanning calorimetry (DSC) at 182.74±3°C when the heating rate is 10°C / min. 11. A cocrystal according to any one of items 1 to 4 above, wherein the powder X-ray diffraction (XRD) pattern includes diffraction peaks at diffraction angles 2θ (±0.2°) of 6.81572°, 7.46604°, 9.87023°, 12.3532°, 13.24°, and 18.6396°. 12. A cocrystal according to any one of items 1 to 4 above, which exhibits an endothermic peak in differential scanning calorimetry (DSC) at 151.69±3°C when the heating rate is 10°C / min. 13. A cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer. 14. The cocrystal according to item 13, which comprises camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer. 15. The cocrystal according to items 13 and 14, wherein the molar ratio of camostat or a pharmaceutically acceptable salt thereof, niclosamide, and the coformer is 1:1:1 to 1:1:6. 16. The cocrystal according to items 13 and 14, wherein the coformer is one or more selected from meglumine, histidine, arginine, nicotinamide, benzoate, formic acid, sorbic acid, citroic acid, malic acid, caffeine, theophylline, and urea. 17. The cocrystal according to items 13 and 14 above, wherein the powder X-ray diffraction (XRD) pattern includes diffraction peaks at diffraction angles 2θ (±0.2°) of 7.0522°, 7.6239°, 9.06226°, 12.4912°, 18.009°, and 21.9897°. 18. A cocrystal according to any one of items 13 to 16, which exhibits an endothermic peak in differential scanning calorimetry (DSC) at 126.03°C when the heating rate is 10°C / min. 19. A method for producing a cocrystal according to any one of items 1 to 12, comprising mixing camostat or a pharmaceutically acceptable salt thereof and niclosamide to co-crystallize them. 20. The method for producing a cocrystal according to any one of items 1 to 12, in item 19, wherein the co-crystallizing step includes mixing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a solvent, and the solvent is one or more selected from water, a linear or branched alcohol having 1 to 5 carbon atoms, acetone, acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), ethyl acetate, toluene, hexane, and tetrahydrofuran. 21. The method for producing a cocrystal according to any one of items 1 to 12, wherein in the cocrystallization step, camostat or a pharmaceutically acceptable salt thereof and niclosamide are fused in a molar ratio of 1:4 to 4:1. 22. The method for producing a cocrystal according to any one of items 1 to 12, wherein in the cocrystallization step, camostat or a pharmaceutically acceptable salt thereof and niclosamide are fused in a molar ratio of 1:1. 23. A method for producing a cocrystal according to any one of items 13 to 18, comprising fusing camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer to form a cocrystal. 24. A pharmaceutical composition for preventing or treating cancer, inflammatory diseases, or viral infections, comprising a cocrystal according to any one of items 1 to 18 as an active ingredient. 25. The pharmaceutical composition according to item 24, wherein the cancer is one or more selected from pancreatic cancer, breast cancer, liver cancer, and lung cancer. 26. The pharmaceutical composition according to item 24, wherein the viral infection disease is one or more selected from coronavirus infection disease, SARS virus infection disease, influenza virus infection disease, and killer tick-borne infection disease. 27. A pharmaceutical composition according to item 24, wherein the inflammatory disease is one or more selected from allergies, dermatitis, atopy, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, ankylosing spondylitis, fibromyalgia, psoriatic arthritis, osteoarthritis, tendonitis, tenosynovitis, peritendinitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, acute inflammatory diseases, and chronic inflammatory diseases. 28. A method for preventing or treating cancer, an inflammatory disease, or a viral infection, comprising administering to an individual a cocrystal according to any one of items 1 to 18. 29. Use of a cocrystal according to any one of items 1 to 18 for the prevention or treatment of cancer, inflammatory diseases or viral infections. 30. Use of a cocrystal according to any one of items 1 to 18 for the manufacture of a medicament for the prevention or treatment of cancer, inflammatory diseases, and viral infectious diseases.

[0007] Pharmaceutical composition, treatment method using same and its use The present invention provides a pharmaceutical composition comprising, as active ingredients, a cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide. The present invention provides a pharmaceutical composition for the prevention or treatment of cancer, an inflammatory disease, or a viral infection, comprising, as active ingredients, a cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide. The present invention provides a pharmaceutical composition comprising, as active ingredients, camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-crystal including a co-former. The present invention provides a pharmaceutical composition for the prevention or treatment of cancer, an inflammatory disease, or a viral infection, comprising as active ingredients camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a cocrystal including a co-former. A pharmaceutical composition containing the cocrystal of the present invention as an active ingredient can be useful for preventing or treating cancer, inflammatory diseases, and viral infections. Pharmaceutical compositions containing the cocrystal of the present invention as an active ingredient can be prepared into tablets, powders, fine granules, granules, capsules, pills, liquids, injections, suppositories, ointments, patches, etc. using commonly used pharmaceutically acceptable carriers, excipients, and other additives, and can be administered orally or parenterally. Specific examples of pharmaceutically acceptable carriers include, but are not limited to, one or more selected from lactose, dextrose, sucrose, sorbitol, mannitol, sugar, fructose, pregelatinized starch, starch, gum arabic, calcium phosphate, carrageenan, sodium carboxymethylcellulose, calcium carboxymethylcellulose, alginate, gelatin, calcium silicate, light anhydrous silicic acid or a derivative thereof, silicon dioxide, polyacrylate or a copolymer thereof, microcrystalline cellulose, polyvinylpyrrolidine, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, minerals, and oils. The formulations can be prepared by conventional methods used in the art, and can be formulated into various formulations depending on the disease or ingredient. Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, etc., and may contain commonly used inert diluents such as purified water, dimethyl sulfoxide (DMSO), polysorbate 20, polysorbate 80, or ethyl alcohol. In addition to the inert diluents, the pharmaceutical compositions may contain auxiliary agents such as solubilizers, dissolution aids, wetting agents, and suspending agents, as well as sweeteners, flavors, fragrances, and preservatives. Injectable preparations for parenteral administration may include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Diluents for aqueous solutions and suspensions include, for example, distilled water for injections and physiological saline. Diluents for non-aqueous solutions and suspensions include, for example, glycols such as propylene glycol and polyethylene glycol; vegetable oils such as olive oil and corn oil; alcohols such as ethyl alcohol; lipophilic surfactants such as Span 80; and hydrophilic surfactants such as Polysorbate 80. The pharmaceutical composition of the present invention may contain additives such as isotonicity agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, solubilizers, or dissolution aids. These can be sterilized by filtration through a bacteria-retaining filter, by adding a disinfectant, or by ultraviolet irradiation. In addition, in the present invention, a sterile solid composition can be prepared and dissolved in a sterilized injectable solvent before use. The dose (therapeutically effective dose) of the cocrystal according to the present invention to an individual can be appropriately determined taking into consideration the indication, severity of the disease, body weight, age, sex, etc., and the administration dose and method of use can be appropriately varied depending on various conditions. The pharmaceutically effective amount and effective dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, mode of administration, administration time and / or route of administration of the pharmaceutical composition, and on many factors including the type and degree of response to be achieved by administration of the pharmaceutical composition, the type, age, weight, general health condition, symptoms and degree of disease, sex, diet, excretion, drugs used simultaneously or at different times in the individual, other components of the composition, etc., as well as similar factors well known in the medical field. A person of ordinary skill in the art can easily determine and prescribe an effective dosage for the intended treatment. The present invention provides a method for preventing or treating cancer, an inflammatory disease, or a viral infection, comprising the step of administering to an individual a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide; or a pharmaceutical composition comprising the same. The present invention provides a method for preventing or treating cancer, an inflammatory disease, or a viral infection, comprising the step of administering to an individual a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former; or a pharmaceutical composition comprising the same. The method for preventing or treating cancer, an inflammatory disease, or a viral infection of the present invention can involve administering a therapeutically effective amount of the cocrystal of the present invention. The cocrystal of the present invention can be usefully used in the prevention or treatment of cancer, inflammatory diseases, or viral infections. The cocrystals of the present invention can be administered to an individual suffering from cancer, an inflammatory disease, or a viral infection. In the present invention, "administration" means introducing a given substance into an individual by an appropriate method. In the present invention, the term "individual" refers to all animals, including rats, mice, livestock, etc., including humans, and specifically may be mammals, including humans, but is not limited thereto. In the present invention, "prevention" refers to any action that suppresses or delays the onset of a disease by administering the cocrystal of the present invention. In the present invention, "treatment" refers to any action that improves or alters the symptoms of a disease-susceptible or disease-affected individual by administering the cocrystal of the present invention. As used herein, the term "therapeutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to any medical treatment and that does not cause side effects, and this amount can be determined by one of ordinary skill in the art based on factors including the patient's sex, age, weight, health status, type and severity of the disease, drug activity, drug sensitivity, administration method, administration time, administration route, excretion rate, treatment duration, co-administered or concomitant drugs, and other factors well known in the medical field. The specific therapeutically effective amount for a particular patient will vary depending on a variety of factors, including the type and degree of response to be achieved, the specific composition including whether other formulations are used, the patient's age, weight, general health status, sex, and diet, administration time, administration route, and excretion rate of the composition, treatment duration, drugs used in conjunction with or concomitantly with the specific composition, and similar factors well known in the medical field. In the present invention, "cancer" refers to lung cancer, pancreatic cancer, gastric cancer, myelodysplastic syndrome, leukemia including acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML), adrenal cancer, anal cancer, basal squamous cell skin cancer, bile duct cancer, bladder cancer, bone cancer, brain and spinal cord tumors, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), colorectal cancer, endometrial cancer, esophageal cancer, Ewing series tumors, eye cancer, gallbladder cancer, gastrointestinal carcinomas, gastrointestinal stromal tumors, The cancer may be one or more selected from the group consisting of gastrointestinal stromal tumor (GIST), trophoblastic disease, glioma, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, hypopharyngeal cancer, liver cancer, lung carcinoid tumor, lymphoma including cutaneous T-cell lymphoma, malignant mesothelioma, melanoma skin cancer, Merkel cell skin cancer, multiple myeloma, nasal cavity and paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, oral and oropharyngeal cancer, osteosarcoma, ovarian cancer, penile cancer, pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, thymic cancer, thyroid cancer including anaplastic thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, and Wilms' tumor. In the present invention, the "inflammatory disease" may be one or more selected from allergies, dermatitis, atopy, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, ankylosing spondylitis, fibromyalgia, psoriatic arthritis, osteoarthritis, tendonitis, tenosynovitis, peritendinitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, acute inflammatory diseases, and chronic inflammatory diseases. In the present invention, the "viral infection disease" may be one or more selected from coronavirus infection disease induced by coronavirus infection, influenza virus infection (virulence) induced by influenza virus infection, SARS virus infection induced by SARS virus infection, and killer tick-borne infection disease induced by killer tick infection. The coronavirus can be one or more selected from alphacoronavirus, betacoronavirus, gammacoronavirus, deltacoronavirus, and variant coronavirus. The coronavirus infection disease may be Severe Acute Respiratory Syndrome (SARS), specifically a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and more specifically, coronavirus disease-19. The cocrystal of the present invention has been confirmed to have excellent antiviral activity against SARS-CoV-2. That is, the cocrystal of the present invention can inhibit cell invasion by SARS-CoV-2. The cocrystal of the present invention can prevent or treat coronavirus disease-19, a disease caused by SARS-CoV-2. Symptoms of SARS-CoV-2 infection disease can include fever, fatigue, cough, difficulty breathing, phlegm, sore throat, headache, hemoptysis, nausea, gastrointestinal symptoms, kidney disease, respiratory disease, diarrhea, etc. The present invention provides use of a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide for the prevention or treatment of cancer, an inflammatory disease, or a viral infection disease. The present invention provides use of a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former for the prevention or treatment of cancer, an inflammatory disease, or a viral infection disease. The present invention provides use of a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide for the manufacture of a medicament for the prevention or treatment of cancer, inflammatory diseases, and viral infections. The present invention provides use of a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former for the manufacture of a medicament for the prevention or treatment of cancer, an inflammatory disease, or a viral infection disease. The items mentioned in each section of the present invention, i.e., cocrystal, production method, pharmaceutical composition, treatment method and use, are equally applicable unless they contradict each other. [Effects of the Invention]

[0008] The cocrystal of the present invention has improved solubility, bioavailability, and biomembrane permeability, and can be useful for treating cancer, inflammatory diseases, and viral infections. The cocrystal of the present invention is a substance having significantly increased solubility and bioavailability compared to existing niclosamide or camostat, and has improved solubility and biomembrane permeability, so it can be effectively used for the prevention and / or treatment of cancer, inflammatory diseases, or viral infectious diseases such as coronaviruses. The cocrystal of the present invention is economical because it is highly safe and easy to store, and can be easily produced in large quantities. [Brief explanation of the drawings]

[0009] [Figure 1] 1 shows the results of powder X-ray diffraction tests (PXRD) of niclosamide, camostat mesylate, camostat, and the cocrystals α, β, γ, δ, and ε of the present application. [Figure 2] 1 shows the results of differential scanning calorimetry (DSC) analysis of niclosamide, camostat mesylate, camostat, and the cocrystals α, β, γ, δ, and ε of the present invention. [Figure 3] 1 shows the results of evaluating the anti-cancer efficacy of the cocrystals of Examples 1 and 17 and a positive control drug in a paclitaxel-resistant breast cancer cell line. [Figure 4] 1 shows the results of evaluating the antiviral efficacy of the cocrystals of Examples 1 and 17 and the positive control drug against SARS-CoV-2. DETAILED DESCRIPTION OF THE INVENTION

[0010] The best mode for carrying out the present invention will now be described in detail. The inventors of the present invention have developed a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide; and a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a coformer, and in order to confirm the cocrystal formation, the produced cocrystals were analyzed by various experimental methods as follows. As described above, the cocrystals of the present invention allow a single cocrystal with consistent quality to be obtained with good reproducibility. Furthermore, the cocrystals of the present invention are crystals of active pharmaceutical ingredients (medicinal raw materials) used in the manufacture of pharmaceuticals, can be supplied stably, and have excellent storage safety. The difference in crystalline form between the simple mixture and the cocrystal is clear from the results of differential scanning calorimetry (DSC) analysis and powder X-ray diffraction (PXRD) analysis. Niclosamide and camostat mesylate are identified by the PXRD diffraction angles, relative intensities, and DSC endothermic peaks shown in Tables 8 and 10 and Figure 1. As the cocrystals of the present invention, cocrystal α, cocrystal β, cocrystal γ, cocrystal δ, and cocrystal ε are identified by the PXRD diffraction angles, relative intensities, and DSC endothermic peaks shown in Tables 9 and 10 and Figure 1. Furthermore, due to the characteristics of XRD diffraction data, the spacing of the crystal lattice and the overall pattern are important in determining the identity of the crystal, and the results of heat flow measurements may vary slightly depending on the direction of crystal growth, particle size, and measurement conditions, so they should not be interpreted too strictly. The method for producing a cocrystal according to the present invention includes a step of mixing camostat or a pharmaceutically acceptable salt thereof and niclosamide to cause co-crystallization, and the co-crystallization step can be carried out by various methods known as methods for producing cocrystals. For example, the cocrystals α, β, γ, δ, and ε according to the present invention can be prepared independently by using a crystallization method such as a liquid-assisted grinding method, a slurry method, or a solvent cooling method. When using the liquid-assisted grinding method, the cocrystal according to the present invention can be prepared by grating and reacting camostat or a pharmaceutically acceptable salt thereof with an alkalizing agent together with a small amount of a solvent such as distilled water using a tool such as a mortar and pestle, and then adding a small amount of distilled water, an organic solvent such as acetone, acetonitrile, tetrahydrofuran, or an alcohol, and niclosamide and continuing to grind. When using the slurry method, the cocrystal according to the present invention can be prepared by adding niclosamide to a supersaturated solution of camostat or a pharmaceutically acceptable salt thereof and an alkalizing agent in distilled water, acetone, acetonitrile, tetrahydrofuran, or an organic solvent such as methanol, ethanol, or isopropyl alcohol, and continuously stirring the mixture. Alternatively, a cocrystal having a different crystalline form can be prepared by adding a dry cocrystal to a specific organic solvent and slurrying it. When using the solvent cooling method, camostat or a pharmaceutically acceptable salt thereof and an alkalizing agent are stirred and reacted in a first solvent such as distilled water, followed by adding a solution of niclosamide completely dissolved in a second solvent such as acetone or an alcohol by heating, and stirring while cooling the solvent to synthesize the cocrystal of the present invention. The volume ratio of the first solvent to the second solvent may be about 10:1 to 1:10. For example, the volume ratio of the first solvent to the second solvent may be about 4:1 to 5:1. In the antisolvent method, camostat mesylate and an alkalizing agent are stirred and reacted in a first solvent such as distilled water, followed by filtration and drying to obtain dry powder camostat, which is then mixed with a solution of niclosamide completely dissolved in a second solvent such as acetone or an alcohol by heating, and the dry camostat is stirred. Distilled water is then added as an antisolvent to produce the cocrystal of the present invention. The alkalizing agent used in the liquid-assisted grinding method, slurry method, solvent cooling method, or anti-solvent method may be one or more selected from basic substances such as sodium bicarbonate (NaHCO3), sodium carbonate (Na2CO3), sodium hydroxide (NaOH), potassium hydroxide (KOH), calcium hydroxide (Ca(OH)2), and magnesium hydroxide (Mg(OH)2), but is not limited thereto. The present invention will be specifically described below by way of examples. That is, the cocrystal containing camostat or a pharmaceutically acceptable salt thereof and niclosamide of the present invention can be prepared by the method described below. However, the use of examples or exemplary language provided in this application is merely intended to more clearly illustrate the present invention and does not limit the scope of the claimed invention.

[0011] <Example> In the examples, niclosamide was purchased from Hengcheng Pharmaceutical Co., Ltd.; camostat mesylate was purchased from MFC Co., Ltd.; alkalinizing agents such as sodium hydroxide, sodium carbonate, and sodium bicarbonate were purchased from Samchun Co., Ltd.; ethanol was purchased from Samchun Co., Ltd.; acetonitrile and acetone were purchased from Daejung Co., Ltd.; and coformers were purchased from Merck Co., Ltd. <Examples 1 to 8> Preparation of cocrystal α In one example of the present invention, cocrystal α according to the present invention was prepared by a slurry method. The contents of niclosamide and camostat mesylate, the type and content of the alkalizing agent, and the types and contents of the first and second solvents were as shown in Table 1 below. Example 1 49.45 g of camostat mesylate was added to 2.5 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 8.4 g of sodium bicarbonate (alkalinizing agent) was added to 0.1 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 32.71 g of niclosamide was added to 2.0 kg of absolute ethanol (solvent 2) at 30°C and stirred at 100 rpm until completely dissolved. The camostat mesylate solution and niclosamide solution were filtered through a 0.45 μm filter to remove any possible foreign matter. The filtered camostat mesylate solution was added to the sodium bicarbonate solution, mixed, and stirred at 100 rpm for 30 minutes. When the mixed solution became sufficiently opaque, the filtered niclosamide solution was added and stirred at 200 rpm for 3 hours. Thereafter, the reactant was filtered using a vacuum pump and a paper filter to remove the solvent, and then dried at 30°C for one day using a vacuum dryer to obtain cocrystal α in the form of a dry powder. Examples 2 to 8 Cocrystals α of Examples 2 to 8 were produced using substantially the same method as in Example 1 above, but using the components and contents listed in Table 1 below. [Table 1] JPEG0007733935000004.jpg105147 <Examples 9 and 16> Preparation of cocrystal β In one example of the present invention, cocrystal β according to the present invention was prepared by a slurry method. The contents of niclosamide and camostat mesylate, the type and content of the alkalizing agent, and the types and contents of the first solvent, second solvent, and third solvent were as shown in Table 2 below. Example 9. 49.45 g of camostat mesylate was added to 2.5 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 8.4 g of sodium bicarbonate (alkalinizing agent) was added to 0.1 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 32.71 g of niclosamide was added to 2.0 kg of ethanol (solvent 2) at 30°C and stirred at 100 rpm until completely dissolved. The camostat mesylate solution and niclosamide solution were filtered through a 0.45 μm filter to remove any foreign matter. The filtered camostat mesylate solution was added to the sodium bicarbonate solution, mixed, and stirred at 100 rpm for 30 minutes. When the mixed solution became sufficiently opaque, the filtered niclosamide solution was added and stirred at 100 rpm for 3 hours. The solvent was then removed by filtering the reactants using a vacuum pump and a paper filter, and the mixture was then dried at 30°C for one day using a vacuum dryer to obtain a cocrystal raw material in the form of a dry powder. The obtained cocrystal raw material was placed in 1.6 kg of anhydrous ethanol (third solvent) at 25°C and stirred at 100 rpm for three hours. The solvent was then removed by filtering the reactants using a vacuum pump and a paper filter, and the mixture was then dried at 25°C for one day using a vacuum dryer to obtain cocrystal β in the form of a dry powder. Examples 10 to 16. Cocrystal β of Examples 10 to 16 were produced using substantially the same method as in Example 9 above, but using the components and contents listed in Table 2 below. [Table 2] JPEG0007733935000005.jpg105152 <Examples 17 to 20> Preparation of cocrystal β In one example of the present invention, the cocrystal β according to the present invention was prepared by a slurry method. The contents of niclosamide and camostat mesylate, the type and content of the alkalizing agent, and the types and contents of the first and second solvents were as shown in Table 3 below. Example 17. 49.45 g of camostat mesylate was added to 2.5 kg of distilled water (first solvent) at 25°C and stirred at 100 rpm until completely dissolved. 10.6 g of sodium carbonate (alkalinizing agent) was added to 0.1 kg of distilled water (first solvent) at 25°C and stirred at 100 rpm until completely dissolved. The camostat mesylate solution was filtered using a 0.45 μm filter to remove any impurities. The filtered camostat mesylate solution was added to the sodium carbonate solution, mixed, and stirred at 100 rpm for 30 minutes. When the mixed solution became sufficiently opaque, the solvent was removed by filtering the reaction mixture using a vacuum pump and a paper filter. The mixture was then dried in a vacuum oven at 25°C for one day to obtain camostat in dry powder form. Next, 32.71 g of niclosamide was added to 1.6 kg of absolute ethanol (second solvent) at 30°C and stirred at 100 rpm until completely dissolved, and then filtered using a 0.45 μm filter to remove any impurities. The filtered niclosamide solution was added to a camostat and stirred at 100 rpm for 3 hours at 25°C. The solvent was then removed by filtering the reaction mixture using a vacuum pump and a paper filter, and the mixture was dried at 25°C for one day in a vacuum dryer to obtain cocrystal β in the form of a dry powder. Examples 18-20. Cocrystal β of Examples 18 to 20 were produced using substantially the same method as that of Example 17 above, but using the components and contents listed in Table 3 below. [Table 3] JPEG0007733935000006.jpg59147 <Examples 21 to 24> Preparation of cocrystal γ In one example of the present invention, the cocrystal γ according to the present invention was prepared by a slurry method. The contents of niclosamide and camostat mesylate, the type and content of the alkalizing agent, and the type and content of the first and second solvents were as shown in Table 4 below. Example 21. 49.45 g of camostat mesylate was added to 2.5 kg of distilled water (first solvent) at 25°C and stirred at 100 rpm until completely dissolved. 8.4 g of sodium bicarbonate was added to 0.1 kg of distilled water (first solvent) at 25°C and stirred at 100 rpm until completely dissolved. The camostat mesylate solution was filtered using a 0.45 μm filter to remove any impurities. The filtered camostat mesylate solution was added to the sodium bicarbonate solution, mixed, and stirred at 100 rpm for 30 minutes. When the mixed solution became sufficiently opaque, the solvent was removed by filtering the reaction mixture using a vacuum pump and paper filter, and the mixture was then dried in a vacuum oven at 25°C for one day to obtain camostat in dry powder form. Next, 32.71 g of niclosamide was added to 1.6 kg of acetone (second solvent) at 30°C and stirred at 100 rpm to completely dissolve, and then filtered using a 0.45 μm filter to remove any impurities. The filtered niclosamide solution was added to a camostat and stirred at 100 rpm for 3 hours at 25°C. The solvent was then removed by filtering the reaction mixture using a vacuum pump and a paper filter, and the mixture was dried at 25°C for one day in a vacuum dryer to obtain cocrystal γ in the form of a dry powder. Examples 22 to 24. Cocrystal γ of Examples 22 to 24 was produced using substantially the same method as that of Example 21, but using the components and contents listed in Table 4 below. [Table 4] JPEG0007733935000007.jpg59147 <Examples 25 to 28> Preparation of cocrystal δ In one example of the present invention, cocrystal δ according to the present invention was prepared by a slurry method. The contents of niclosamide and camostat mesylate, the type and content of the alkalizing agent, and the types and contents of the first, second, third, and fourth solvents were as shown in Table 5 below. Example 25. 49.45 g of camostat mesylate was added to 2.5 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 8.4 g of sodium bicarbonate (alkalinizing agent) was added to 0.1 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 32.71 g of niclosamide was added to 1.6 kg of acetone (solvent 2) at 30°C and stirred at 100 rpm until completely dissolved. The camostat mesylate solution and niclosamide solution were filtered through a 0.45 μm filter to remove any possible foreign matter. The filtered camostat mesylate solution was added to the sodium carbonate solution, mixed, and stirred at 100 rpm for 30 minutes. When the mixed solution became sufficiently opaque, the filtered niclosamide solution was added and stirred at 100 rpm for 3 hours. The reaction mixture was then filtered using a vacuum pump and a paper filter to remove the solvent, followed by drying at 30°C for one day in a vacuum oven to obtain a dry powder of cocrystal raw material. The obtained cocrystal raw material was placed in 1.6 kg of anhydrous ethanol (solvent 3) at 25°C and stirred at 100 rpm for three hours. The reaction mixture was then filtered using a vacuum pump and a paper filter to remove the solvent, followed by drying at 25°C for one day in a vacuum oven to obtain a dry powder of cocrystal raw material. The obtained cocrystal raw material was placed in 1.6 kg of acetonitrile (solvent 4) at 25°C and stirred at 100 rpm for three hours. The reaction mixture was then filtered using a vacuum pump and a paper filter to remove the solvent, followed by drying at 25°C for one day in a vacuum oven to obtain cocrystal δ in dry powder form. Examples 26 to 28. Cocrystal δ of Examples 26 to 28 was prepared using substantially the same method as in Example 25 above, but using the components and contents listed in Table 5 below. [Table 5] JPEG0007733935000008.jpg81152 <Examples 29 to 32> Preparation of cocrystal δ In one example of the present invention, cocrystal δ according to the present invention was prepared by a slurry method. The contents of niclosamide and camostat mesylate, the type and content of the alkalizing agent, and the types and contents of the first and second solvents were as shown in Table 6 below. Example 29. 49.45 g of camostat mesylate was added to 2.5 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 8.4 g of sodium carbonate (alkalinizing agent) was added to 0.1 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. The camostat mesylate solution was filtered through a 0.45 μm filter to remove any impurities. The filtered camostat mesylate solution was added to the sodium carbonate solution, mixed, and stirred at 100 rpm for 30 minutes. When the mixed solution became sufficiently opaque, the solvent was removed by filtering the reaction mixture using a vacuum pump and paper filter. The mixture was then dried at 25°C in a vacuum oven for one day to obtain camostat in dry powder form. 32.71 g of niclosamide was then added to 1.6 kg of acetonitrile (solvent 2) at 30°C, and the resulting camostat was added and stirred at 100 rpm for 3 hours. Thereafter, the reactant was filtered using a vacuum pump and a paper filter to remove the solvent, and then dried at 30°C for one day using a vacuum dryer to obtain cocrystal δ in the form of a dry powder. Examples 30 to 32. Cocrystal δ of Examples 30 to 32 was produced using substantially the same method as that of Example 29, but using the components and contents listed in Table 6 below. [Table 6] JPEG0007733935000009.jpg59147 <Examples 33 to 40> Preparation of cocrystal ε In one example of the present invention, cocrystal δ according to the present invention was prepared by a slurry method. The contents of niclosamide, camostat mesylate, and meglumine, the type and content of the alkalizing agent, and the types and contents of the first, second, and third solvents were as shown in Table 7 below. Example 33. 49.45 g of camostat mesylate was added to 2.5 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 10.5 g of sodium carbonate was added to 0.1 kg of distilled water (solvent 1) at 25°C and stirred at 100 rpm until completely dissolved. 32.71 g of niclosamide was added to 2.0 kg of absolute ethanol (solvent 2) at 30°C and stirred at 100 rpm until completely dissolved. The camostat mesylate solution and niclosamide solution were filtered through a 0.45 μm filter to remove any possible foreign matter. The filtered camostat mesylate solution was added to the sodium carbonate solution, mixed, and stirred at 100 rpm for 30 minutes. When the mixed solution became sufficiently opaque, the filtered niclosamide solution was added and stirred at 100 rpm for 3 hours. The solvent was then removed by filtering the reactants using a vacuum pump and a paper filter, and the mixture was then dried at 30°C for one day using a vacuum dryer to obtain a cocrystal raw material in the form of a dry powder. The obtained cocrystal raw material was added to 1.6 kg of acetonitrile (third solvent) at 25°C along with 97.6 g of meglumine (coformer), and the mixture was stirred at 100 rpm for three hours. The solvent was then removed by filtering the reactants using a vacuum pump and a paper filter, and the mixture was then dried at 20°C for one day using a vacuum dryer to obtain cocrystal ε in the form of a dry powder. Examples 34 to 40. Cocrystal ε of Examples 34 to 40 were prepared using substantially the same method as in Example 33, but using the components and contents listed in Table 7 below. [Table 7] JPEG0007733935000010.jpg150152 The production yield of the cocrystal of the present invention produced in Examples 1 to 40 was 70% or more, and the purity was at least 95% or more. The analytical experiments for the cocrystals α, β, γ, δ, and ε produced in Examples 1, 17, 21, 25, and 33 and the results thereof will be described in more detail below. <Experimental Example> The cell lines used in the experiments were purchased from the American Type Culture Collection (ATCC) or the Korean Cell Line Bank (KCLB). Experimental Example 1: Powder X-ray Diffraction (PXRD) Analysis Powder X-ray diffraction (PXRD) analysis was performed on each of the cocrystal samples according to Examples 1, 17, 21, 25, and 33 of the present invention and the comparative samples (niclosamide, camostat, and camostat mesylate) using a D8 ADVANCE with Davinci (trade name, Bruker AXS Inc., GmbH, Germany) powder X-ray diffraction analyzer under the following conditions. Detector: High-speed LynxEye detector Tube:Cu Tube current: 40mA Tube voltage: 40kV Sampling width: 0.020° Scanning speed: 0.1sec / step Wavelength: 1.54056Å Measurement diffraction angle range (2θ): 2.5 to 40° The cocrystal samples of the present invention are the cocrystals in the form of dry powder obtained in Examples 1, 17, 21, 25, and 33, respectively, and the comparative samples are the raw materials used to form the cocrystals: niclosamide, camostat, and camostat mesylate. The diffraction angles (2θ) of the major X-ray diffraction patterns obtained through PXRD analysis of the cocrystal samples of Examples 1, 17, 21, 25, and 33 of the present invention and the comparative samples, along with their relative intensities, are shown in Tables 8 and 9 below. [Table 8] JPEG0007733935000011.jpg106147[Table 9] JPEG0007733935000012.jpg198147 In FIG. 1, the x-axis is 2θ (Bragg angle, unit: °), and the y-axis is X-ray intensity (cps). 1, it can be seen that the process of forming the cocrystal of the coformer involves a non-stoichiometric hydrate, which causes a shift in the distance and a shift in the diffraction angle (20). In other words, when compared with niclosamide, camostat mesylate, and camostat in FIG. 1, it can be seen that the cocrystal of the present invention is a new crystalline form that exhibits a diffraction pattern different from that of the raw material. Experimental Example 2: Differential scanning calorimetry (DSC) analysis Differential scanning calorimetry (DSC) analysis was performed on niclosamide, camostat mesylate, camostat, and the cocrystals prepared in Examples 1, 17, 21, 25, and 33. For differential scanning calorimetry (DSC) analysis, a DSC Q2000 System (product name, TA Instrument, USA) was used as the DSC analyzer, and measurements were performed by increasing the temperature from 0°C to the melting point at a heating rate of 10°C / min. N2 gas was supplied at a rate of 50 mL / min, and measurements were performed in an aluminum sample pan. Samples were analyzed using Universal Analysis 2000 software (product name, TA Instruments, USA). The maximum endothermic peak temperatures of the individual components niclosamide, camostat, and their fused crystals obtained through DSC analysis are shown in Table 10 below and Figure 2. [Table 10] JPEG0007733935000013.jpg78147In FIG. 2, the x-axis represents temperature (unit: °C) and the y-axis represents heat flow (unit: W / g). Referring to Table 10 above together with FIG. 2 , it can be seen that when the heating rate is 10°C / min, cocrystal α shows an endothermic peak in differential scanning calorimetry (DSC) at 144.38°C, cocrystal β shows an endothermic peak in differential scanning calorimetry (DSC) at 126.35°C, cocrystal γ shows an endothermic peak in differential scanning calorimetry (DSC) at 182.74°C, cocrystal 5 shows an endothermic peak in differential scanning calorimetry (DSC) at 151.69°C, and cocrystal ε shows an endothermic peak in differential scanning calorimetry (DSC) at 126.03°C. In other words, when compared with each of niclosamide, camostat mesylate, and camostat, it can be confirmed that the cocrystal of the present invention is a new crystal that exhibits new thermodynamic properties different from those of the raw materials. Experimental Example 3. Evaluation of niclosamide solubility in the present cocrystal The solubility of niclosamide contained in single substance niclosamide and the cocrystals prepared in Examples 17 and 33 of the present application was measured and compared in a pH 7 buffer solution. The pH 7 buffer solution was prepared by mixing 0.1 N potassium phosphate and 0.1 N sodium hydroxide. 5 mg of each of single substance niclosamide, cocrystal β from Example 17, and cocrystal ε from Example 33 was added to 25 mL of the prepared pH solution at room temperature and stirred at 600 rpm. After stirring for 1 hour, 5 mL of the supernatant was removed and filtered through a 0.45 μm PVDF filter. The filtered solution was used as a sample to evaluate the amount of dissolved niclosamide. The HPLC instrument conditions were a flow rate of 1.5 ml / min, an injection volume of 100 μl, a detection wavelength of 287 nm, and a column oven temperature of 25°C. Mobile phase A was a pH 6 buffer solution (potassium phosphate 2 g / L, disodium phosphate 1 g / L, tetrabutylammonium hydrogen sulfate 2 g / L, adjusted to pH 6.0 ± 0.05 with 1M NaOH), and mobile phase B was acetonitrile. The mobile phase conditions are as shown in Table 11 below. [Table 11] JPEG0007733935000014.jpg47147Referring to Table 12 below, niclosamide has low solubility at pH 7 and is difficult to detect, but in the cocrystal of Example 17, niclosamide was dissolved at 55.2 μg / ml, demonstrating a significant improvement in solubility compared to niclosamide alone.In addition, in the cocrystal of Example 33, niclosamide was dissolved at 0.4 μg / ml, demonstrating a significant improvement in solubility compared to niclosamide alone. [Table 12] JPEG0007733935000015.jpg21147 Experimental Example 4: Evaluation of the artificial membrane permeability of the present cocrystal in camostat The artificial membrane permeability of the camostat cocrystal prepared in Example 21 was evaluated using a side-by-side cell system and compared with that of the single camostat. For the artificial membrane, 200 μL of GIT-0-Lipid solution was instilled into the center of a 25 mm hydrophobic PVDF membrane. 5 mL of 37°C pH 5.0 FeSSIF solution was placed in a donor cell, and 20 mg of sample was weighed and administered to the donor cell. The test was initiated after 5 mL of ethyl alcohol: pH 7.4 PBS buffer (1:9, v / v) solution was added to the acceptor cell. Five 200 μL samples were taken from the acceptor cell at set intervals and used as test solutions. 1 mL of ethyl alcohol: pH 7.4 PBS buffer (1:9, v / v) solution was then added to the acceptor cell to maintain a total volume of 5 mL. [Table 13] JPEG0007733935000016.jpg21147 Referring to Table 13 above, the cumulative permeation amount of Camostat for a single substance was 561.89, while the cumulative permeation amount of Camostat for the cocrystal of Example 21 was 876.29, confirming that the cumulative permeation amount of Camostat was 1.56 times better. In other words, it was confirmed that the cocrystal of the present invention has excellent membrane permeability and therefore has an excellent absorption rate in the body. Experimental Example 5: Evaluation of the artificial membrane permeability of the present cocrystal niclosamide The permeability of the cocrystal of Example 17 of this application to niclosamide through an artificial membrane (PermeaPad barrier membrane, 25 mm) was evaluated using a side-by-side cell system and compared with that of niclosamide alone. Five milliliters of a pH 6.5 FeSSIF solution (37°C) supplemented with 3% (w / w) Kolliphor ELP was placed in a donor cell, and 20 mg of the test sample was administered to donor cell 1. 5 ml of a pH 7.4 PBS solution supplemented with 20% (w / w) HP-β-CD was placed in acceptor cell 1, and the test was initiated. Five 200 μl samples were taken at designated intervals in the acceptor cell. Finally, 1 ml of a pH 7.4 PBS solution supplemented with 20% (w / w) HP-β-CD was placed in the acceptor cell to maintain a total volume of 5 ml. [Table 14] JPEG0007733935000017.jpg21147 Referring to Table 14 above, the cumulative permeation amount of niclosamide alone was 1.18, while the cumulative permeation amount of niclosamide of the cocrystal of Example 17 was 2.03, confirming that the cumulative permeation amount of niclosamide of the cocrystal of the present application was 1.72 times greater. In other words, it was confirmed that the cocrystal of the present invention has excellent membrane permeability and therefore has an excellent absorption rate in the body. Experimental Example 6: Evaluation of cancer cell proliferation inhibitors The cocrystals of the present invention were evaluated as cytostatics to verify their anti-cancer efficacy in pancreatic cancer, breast cancer, non-small cell lung cancer, and liver cancer cell lines. The conditions for the anticancer in vitro efficacy test to evaluate the growth inhibitory properties of the cocrystal of the present invention in each cancer cell line are as shown in Table 15. Hereinafter, cocrystal α refers to the cocrystal produced in Example 1. A total of eight cell lines, including two pancreatic cancer cell lines (PANC-1 and MIAPACA-2), two breast cancer cell lines (MCF-7 and MDA-MB-231), two non-small cell lung cancer cell lines (A-549 and H-1299), and two liver cancer cell lines (Hep-3B and Huh-7), were cultured at 2 × 10 cells per well in a 96-well tissue culture plate. 3 ~4×10 3Cells were seeded in the cell culture medium. After 24 hours of incubation, the cells were treated with each cocrystal drug at six concentrations: 0.3, 3, 30, 300, 3,000, and 30,000 ng / mL. 48 hours after drug treatment, the CCK-8 assay kit was used to observe the color change after 1 to 4 hours of incubation. The absorbance island was measured at 450 nm using a microreader to determine cell viability. [Table 15] JPEG0007733935000018.jpg78147To verify the anticancer efficacy of the cocrystals against various types of cancer cells, cell viability was measured in pancreatic cancer, breast cancer, non-small cell lung cancer, and liver cancer cells to obtain IC 50 The results are shown in Table 16 below. IC of positive control group 50 The values ​​are based on the facts described in the following documents. Gemcitabine:HONGGANG WANG, BEVERLY R.WORD and BEVERLY D.LYN-COOK:Enhanced Efficacy of Gemcitabine by Indo1e-3-carbino1 in Pancreatic Cell Lines:The Role of Human Equi1ibrative Nucleoside Transporter 1.Anticancer research 31(10):3171-3180, 2011. Gefitinib: CHI PAN, HUIJIE DUAN, YINAN WU, CHUNPENG ZHU, CHENGHAO YI, YIN DUAN, DEMIN LU, CHENG GUO, DEQI WU, YANYAN WANG, XIANHUA FU, JING XU, YIDING CHEN, MENG LUO, WEI TIAN, TAO PAN, WENHONG XU, SUZHAN ZHANG and JIANJIN HUANG: Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC. International journal of oncology 57:939-955, 2020 Docetaxel: Aliakbar Taherian, 1Tahereh Mazoochi: Different Expression of Extracellular Signa1-Regu1ated Kinases(ERK) 1 / 2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel. Iranian Journal of basic Medical sciences 15, 669-677, 2012 Sorafenib: Y-C Shen 1, D-L Ou, C Hsu, K-L Lin, C-Y Chang, C-Y Lin, S-H Liu, A-L Cheng: Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. BJC 108, 72-81, 2013 [Table 16] JPEG0007733935000019.jpg 66147 Referring to Table 16 above, the IC of the co-crystal of Example 1 according to the present invention 50The concentrations were confirmed as follows: 99.30 nM in pancreatic cancer cell line PANC-1 cells, 729.32 nM in MIAPACA-2 cells; 427.86 nM in breast cancer cell line MCF-7 cells, 126.31 nM in MDA-MB-231 cells; 975.81 nM in non-small cell lung cancer cell line A-549 cells, 381.13 nM in H-1299 cells; 41.33 nM in liver cancer cell line Hep-3B cells, 134.45 nM in Huh-7 cells. This resulted in the IC of the cocrystal of Example 1. 50 The IC value was confirmed for a total of eight cell lines, two each of pancreatic cancer, breast cancer, non-small cell lung cancer, and liver cancer cell lines, and a low IC value was found for pancreatic cancer cell lines, which are still classified as intractable cancers and have no therapeutic agents. 50 The IC value was confirmed and it was confirmed that it can be effectively used as a growth inhibitor for pancreatic cancer cells. In addition, under the relevant test conditions, it showed low IC values ​​in breast cancer, non-small cell lung cancer, and liver cancer cell lines. 50 The values ​​were confirmed, thereby confirming the cancer cell growth inhibitory effect of the cocrystal of the present invention. In addition, the IC of the positive control group and the cocrystal of Example 1 50 To compare the IC of gemcitabine, a drug used to treat pancreatic cancer patients; gefitinib, a drug used to treat non-small cell lung cancer patients; docetaxel, a drug used to treat breast cancer patients; and sorafenib, a drug used to treat liver cancer patients. 50 was confirmed through the literature. When compared with the positive control drug, the cocrystal of Example 1 of the present application had a significantly lower IC than the positive control drug in all cell lines. 50 It was confirmed that the IC value of the cocrystal of the present invention was higher than that of gemcitabine. 50 The effect of rifampin on IL-1 expression was 432-fold lower in PANC-1 cells and 127-fold lower in MIAPACA-2 cells. It was 13-fold lower in A-549 cells and 45-fold lower in H-1299 cells compared to gefitinib. It was 1.7-fold lower in MCF-7 cells and 5-fold lower in MDA-MB-231 cells compared to docetaxel. It was 297-fold lower in Hep-3B cells and 44-fold lower in Huh-7 cells compared to sorafenib. In other words, it was confirmed that the cocrystal of the present invention has superior efficacy as a cancer cell growth inhibitor compared to conventionally used cancer therapeutic agents. Experimental Example 7: Comparison and verification of the anti-cancer efficacy of the present cocrystal and a positive control group in subtyped breast cancer cell lines The cocrystal of the present invention was evaluated as a cytostatic agent in subtype-specific breast cancer cell lines, and the conditions for the anticancer in vitro efficacy evaluation test for the evaluation were as shown in Table 17 below. The cocrystals of the present invention were tested on a total of 19 types of breast cancer cell lines. The drugs listed in Table 17 below were used as positive controls. The cocrystals prepared in Examples 1 and 17 were serially diluted in half-fold to eight different concentrations for each cell line, and a luminescent cell viability assay was performed using CellTiter-Glo. CellTiter-Glo Substrate and CellTiter-Glo Buffer were mixed to prepare CellTiter-Glo Reagent, and then the same volume of CellTiter-Glo Reagent as the cell culture medium (40 μl volume) was added. The mixture was left at room temperature for 10 minutes, and then measured using a luminometer (GloMax®). Drug susceptibility was confirmed by measuring ATP using a Discover Microplate Reader. IC was calculated using nonlinear regression analysis with GraphPad Prism 9 software. 50 The values ​​were calculated and compared. [Table 17] JPEG0007733935000020.jpg153147To verify the anticancer efficacy of the present cocrystals against subtyped breast cancer cell lines, a dose-response curve test was conducted on a total of 19 types of breast cancer cells, and cell viability was measured to determine the IC 50 Representative results are shown in FIG. 3 and Tables 18 to 21 below. [Table 18] JPEG0007733935000021.jpg27147[Table 19] JPEG0007733935000022.jpg34150[Table 20] JPEG0007733935000023.jpg34150[Table 21] JPEG0007733935000024.jpg32150 Drug responses varied depending on the cell line, but the IC values ​​of the drugs used in Examples 1 and 17, as well as the control drugs, were significantly higher in all cell lines. 50 I was able to secure the value. In the case of hormone-positive breast cancer cell lines, Examples 1 and 17 had lower IC than the positive controls Tamoxifen and Docetaxel. 50 In particular, in the case of ZR-75-1 cells, Example 1 had an IC value 1.7 times lower than that of tamoxifen, and Example 17 had an IC value 1.4 times lower than that of tamoxifen. 50 This confirmed that the cocrystal of Example 1 and Example 17, which is the cocrystal of the present invention, exhibits a more excellent anti-cancer effect than the positive control drug currently being used in hormone-positive breast cancer patients. In the case of HER2-positive breast cancer cell line HCC1419 cells, Example 1 had a significantly lower IC of 19 times and Example 17 had a significantly lower IC of 16 times compared to the positive control drug Herceptin. 50 It was confirmed that the cocrystal of the present invention also showed a significantly lower IC value against MDA-MB-453 cells. 50 In other words, it was confirmed that the effect of the cocrystal of the present invention on reducing cell viability in HER2-positive breast cancer cell lines was significantly superior to that of the positive control group. In the case of triple-negative breast cancer cell lines, the most widely known MDA-MB-231 cells, the IC2000 was 14-fold and 11-fold lower than the positive control drug Cisplatin in both Examples 1 and 17. 50 The anti-cancer effect of the present cocrystal was confirmed to be far superior to that of existing therapeutic agents, even in triple-negative breast cancer cell lines, which are the most difficult to treat among breast cancers. Using drug-resistant breast cancer cell lines that were exposed to doxorubicin, paclitaxel, tamoxifen, or herceptin for a long period of time and developed resistance to the drugs, the IC values ​​of Examples 1 and 17 and the positive control drugs paclitaxel and docetaxel were measured. 50 In drug-resistant breast cancer cell lines, the cocrystals of the examples of this application showed lower IC than the positive control drug Docetaxel. 50In particular, in a breast cancer cell line resistant to Paclitaxel, a representative drug used as a cytotoxic therapeutic agent, Example 1 and Example 17 had IC values ​​that were more than two times lower. 50 I was able to secure the value. Experimental Example 8: Evaluation of the antiviral efficacy of the present cocrystal against SARS-CoV-2 in comparison with a positive control drug An experiment to verify the antiviral efficacy of the present cocrystal against SARS-CoV-2 was conducted using a SARS-CoV-2 cell infection model, and the experimental conditions are as shown in Table 22. Groups treated with the drugs chloroquine, lopinavir, or remdesivir were used as positive controls. To test the antiviral efficacy of the present cocrystals against SARS-CoV-2, 1.2 x 10 sucrose solution was added to a 384-well tissue culture plate containing 1.2 x 10 sucrose solution per well. 4 Vero cells were inoculated with 1000 μM of cocrystals or positive control drugs, which were serially diluted 2-fold in DMS0. After 24 hours, the cells were treated with 50 μM of the highest concentration of cocrystals or positive control drugs, which were prepared in 10-point series. Approximately 1 hour after treatment with the cocrystals or positive control, the cells were infected with SARS-CoV-2 (provided by the Korea Centers for Disease Control and Prevention (KCDC) at 0.125 M0I) in a Biosafety Level 3 (BSL3) facility and cultured at 37°C for 24 hours. The cells were then fixed with 4% paraformaldehyde (PFA) and permeabilized. The cells were then stained with anti-SARS-CoV-2 nucleocapsid (N) primary antibody, Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody, and Hoechst 33342. Fluorescent images of infected cells were captured using the Operetta (Perkin Elmer) high-capacity image analysis instrument. [Table 22] JPEG0007733935000025.jpg129149 To verify the antiviral efficacy of the cocrystals against SARS-CoV-2, a dose-response curve study was conducted in a SARS-CoV-2 cell infection model, and the results are shown in Table 23 below. The selectivity index (SI) value was 0.01 for CC 50 / I C 50was calculated. [Table 23] JPEG0007733935000026.jpg40147 Referring to Table 23, the IC of the cocrystal of Example 1 and Example 17 50 is shown as 0.16 μm, and CC 50 The SI was confirmed to be 50 μm or more, 306 for the cocrystal of Example 1, and 313 for the cocrystal of Example 17. The IC of the positive control drug remdesivir, which is currently being used as a coronavirus treatment drug, was 50 is 3.48 μm, and the IC of the cocrystal 50 In addition, the value was confirmed to be approximately 21.75 times higher than that of the AIDS treatment drug lopinavir, which has been attracting attention as a coronavirus treatment. 50 is 10.30 μm and the IC of the cocrystal of the present application 50 In addition, the IC value for chloroquine, a malaria treatment, was approximately 64.38 times higher than that of 50 is 7.47 μm and the IC of the cocrystal of the present invention 50 The value was approximately 46.69 times higher than that of Through this, the cocrystal of this application has a significantly lower IC than the drug remdesivir, which is currently used as a COVID-19 treatment. 50 It was confirmed that the compound had excellent antiviral effects. Additionally, the present cocrystals were confirmed to have a significantly higher selectivity index (SI) against viruses compared to the positive control group. The selectivity index is an index that shows the ratio of antiviral activity to cytotoxicity, and a higher SI indicates greater effectiveness and safety. Therefore, it was confirmed that the cocrystals can selectively inhibit the proliferation of the SARS-CoV-2 virus. Although the present invention has been described above with reference to one embodiment, it will be understood by those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit and scope of the present invention as defined in the following claims. Accordingly, the true scope of the present invention is to be defined by the appended claims and their equivalents.

Claims

1. A cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide, The powder X-ray diffraction (XRD) pattern contains diffraction peaks at diffraction angles 2θ (2θ) of 5.37715°, 15.1122°, 18.2258°, 18.7579°, 20.3344°, 25.596°, and 26.069° (±0.2°), and shows a differential scanning calorimetry (DSC) endothermic peak at 144.38±3°C when heated at a rate of 10°C / min.

2. A cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide, The powder X-ray diffraction (XRD) pattern contains diffraction peaks at diffraction angles 2θ (±0.2°) of 6.55954°, 10.7176°, 18.147°, 19.5855°, 21.3591°, and 26.8178°, When the heating rate is 10℃ / min, a DSC endothermic peak is observed at 126.35±3℃, which is a cocrystal.

3. A cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide, The XRD pattern contains diffraction peaks at diffraction angles 2θ (±0.2°) of 11.3876°, 16.0975°, 16.6493°, 18.679°, 23.0539°, 23.9013°, 24.4333°, and 29.7344°, and shows a DSC endothermic peak at 182.74±3°C when the heating rate is 10°C / min.

4. A cocrystal comprising camostat or a pharmaceutically acceptable salt thereof and niclosamide, The XRD pattern contains diffraction peaks at diffraction angles 2θ (±0.2°) of 6.81572°, 7.46604°, 9.87023°, 12.3532°, 13.24°, and 18.6396°, and shows a DSC endothermic peak at 151.69±3°C when the heating rate is 10°C / min. Cocrystal.

5. 5. The cocrystal of any one of claims 1 to 4, wherein the molar ratio of camostat or a pharmaceutically acceptable salt thereof to niclosamide is 1:4 to 4:

1.

6. A co-crystal comprising camostat or a pharmaceutically acceptable salt thereof, niclosamide, and a co-former, The XRD pattern contains diffraction peaks at diffraction angles 2θ (±0.2°) of 7.0522°, 7.6239°, 9.06226°, 12.4912°, 18.009°, and 21.9897°, and shows a DSC endothermic peak at 126.03°C when the heating rate is 10°C / min. Cocrystal.

7. 7. The cocrystal of claim 6, wherein the molar ratio of camostat or a pharmaceutically acceptable salt thereof, niclosamide, and coformer is 1:1:1 to 1:1:

6.

8. 7. The co-crystal of claim 6, wherein the co-former is one or more selected from meglumine, histidine, arginine, nicotinamide, benzoate, formic acid, sorbic acid, citric acid, malic acid, caffeine, theophylline, and urea.

9. A pharmaceutical composition for preventing or treating cancer, inflammatory diseases, or viral infections, comprising the cocrystal according to any one of claims 1 to 4 and claim 6 as an active ingredient.

10. 10. The pharmaceutical composition according to claim 9, wherein the cancer is one or more selected from pancreatic cancer, breast cancer, liver cancer, and lung cancer.

11. 10. The pharmaceutical composition according to claim 9, wherein the inflammatory disease is one or more selected from allergies, dermatitis, atopy, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, ankylosing spondylitis, fibromyalgia, psoriatic arthritis, osteoarthritis, tendonitis, tenosynovitis, peritendinitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases.

12. The pharmaceutical composition according to claim 9, wherein the viral infection disease is one or more selected from the group consisting of novel coronavirus infection, SARS virus infection, influenza virus infection and killer tick-borne infection.

Images